Abstract 2430
Background
Colorectal mucosa associated lymphoid tissue (MALT) lymphoma (CML) is rare and comprises only 2.5% of the MALT lymphomas. Its etiology and treatment are not well established. The aim of this systematic literature review is trying to characterize CML and analyzing treatment failure cases treated with various therapeutic strategies.
Methods
We reviewed cases reports on colorectal lymphoma from 1993 to 2017. A PubMed search of the English medical literature was conducted using the search words "colon," "rectum," and "Maltoma" or “MALT lymphoma” as filters. Through the review, 65 case reports were found, of which 15 case reports were excluded, due to literature written in languages other than English, poorly documented cases and combined colonic disease such as adenocarcinoma or inflammatory bowel disease. After all, 67 patients reported in 50 studies were included from PubMed search. And we added 6 patients treated for CML in our multicenter institutes. Risk factor analysis was done for treatment failure, defined as remission failure and recurrence.
Results
Of 73 patients diagnosed as CML, tumors were located in rectum in 54 patients (74.0%), 10 patients (13.6%) in right colon, 3 patients (4.1%) in the transverse colon and 6 patients (8.2%) in the sigmoid colon. The patients were achieved complete response (CR) with surgery (18/19cases), local resection (18/19 cases), chemotherapy (12/13 cases), radiation therapy (4/5cases), or antibiotics therapy including Helicobacter pylori (H. pylori) eradication (12/15 cases) in the first-line treatment. Eight cases (10.9%) needed second-line treatment for remission failure, CR was achieved in 5. The tumor recurrence occurred in 5 patients in remission patients (6.8%). The multivariable analysis showed that male, multiple tumor, first-line treatment failure was significantly related with treatment failure (p = 0.03, p = 0.05, p = 0.03, respectively).
Conclusions
Complete regression of primary CML was achieved using various therapeutic strategies. The first-line treatment failure, multiple tumors were associated with treatment failure, although the numbers of failure cases are too small to draw definitive conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5751 - Phase 3 ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
Presenter: Sanjay Popat
Session: Poster Display session 1
Resources:
Abstract
5103 - CANOPY phase 3 program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)
Presenter: Luis Paz-Ares
Session: Poster Display session 1
Resources:
Abstract
3666 - The Elderly Patient Individualized Chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer.
Presenter: Francesco Passiglia
Session: Poster Display session 1
Resources:
Abstract
4799 - KEYNOTE-495/KeyImPaCT: A Randomized, Biomarker-Directed, Phase 2 Trial of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer (NSCLC)
Presenter: Martin Gutierrez
Session: Poster Display session 1
Resources:
Abstract
6035 - Safety, tolerability and activity of autologous T cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non small cell lung cancer: A Phase 1b/2a randomised pilot study
Presenter: Karen Reckamp
Session: Poster Display session 1
Resources:
Abstract
2176 - IFCT-1701 DICIPLE: a randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
Presenter: Gerard Zalcman
Session: Poster Display session 1
Resources:
Abstract
2352 - ATALANTE-1 randomized phase 3 trial, OSE-2101 versus standard treatment as second or third line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients
Presenter: Enriqueta Felip
Session: Poster Display session 1
Resources:
Abstract
2451 - Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours
Presenter: Nicolas Girard
Session: Poster Display session 1
Resources:
Abstract
4285 - Radiosurgery followed by Tumor Treating Fields (TTFields) for brain metastases (1-10) from NSCLC in the phase 3 METIS trial
Presenter: Minesh Mehta
Session: Poster Display session 1
Resources:
Abstract
4909 - Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): the SQUINT trial
Presenter: Lorenza Landi
Session: Poster Display session 1
Resources:
Abstract